Abstract
The effects of the CCKB receptor antagonists L-365,260, CI-988 and L-740,093, a new compound with improved bioavailability and CNS penetration, were assessed for anxiolytic-like effects in three rat anxiolytic screens sensitive to benzodiazepines, the elevated plus maze (EPM), conditioned suppression of drinking (CSD) and conditioned emotional response (CER) tests. In the EPM, L-740,093 (0.1–1.0 mg/kg), L-365,260 (0.00001–10.0 mg/kg), and CI-988 (0.01–1.0 mg/kg) did not increase the time spent on the open arms of the maze or the number of entries onto the open arms. In contrast, the benzodiazepine receptor partial agonist, bretazenil (0.3–10.0 mg/kg), significantly increased both the time spent on the open arms and the number of open arm entries. In the CSD and the CER tests, L-740,093 (0.1–1.0 mg/kg) L-365,260 (0.0001–0.1 mg/kg) and CI-988 (0.01–10.0 mg/kg) failed to increase suppression ratios compared to the vehicle-treated control rats, whereas, the benzodiazepine receptor partial agonist FG 8205 (10.0 mg/kg) (CSD) and bretazenil (0.3–3.0 mg/kg) (CER) both significantly increased suppression ratios compared to vehicle-treated control rats. In addition, L-365,260 (1.0–50.0 mg/kg), CI-988 (0.1–10.0 mg/kg) and diazepam (0.1–1.0 mg/kg) were assessed in a squirrel monkey conflict procedure. Although diazepam significantly increased suppressed lever pressing rates, L-365,260 and CI-988 were without effect. The present findings provide little support for the hypothesis that CCKB receptor antagonists have anti-anxiety effects in animals.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bayley P, Dawson GR (1993) The effect of i.v. administration of CCK-4 on lever pressing rates of rats on an operant random interval schedule. Br J Pharmacol 108:244P
Bock MG, DiPardo RM, Evans BE, Rittle KE, Whitter WL, Veber DF, Anderson PS, Freidinger RM (1989) Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J Med Chem 32:13–16
Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinintetrapeptide induces panic attack in patients with panic disorder. Can J Psychiatry 35:83–85
Chang RSL, Lotti VJ (1986) Biochemical and pharmacological characterisation of an extremely potent and selective non-peptide cholecystokinin antagonist. Proc Natl Acad Sci USA 83:4923–4926
Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991) Anxiolytic effects of CCK-B antagonists. Neuropeptides 19:65–73
De Montigny C (1989) Cholecystokinin-tetrapeptide induces panic attacks in healthy volunteers. Arch Gen Psychiatry 46:511–17
Dews PB, DeWeese (1977) Schedules of reinforcement. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology (7). Plenum Press N.Y. pp 107–150
Dooley DJ, Klamt I (1993) Differential profile of the CCKBreceptor antagonist CI-988 and diazepam in the four-plate test. Psychopharmacology 112:452–454
Dourish CD, Rycroft W, Dawson GR, Tattersall FD, Iversen SD (1990) Anxiolytic effects of the CCK antagonists devazepide and L-365,260 in a conditioned suppression of drinking model. Eur J Neurosci Suppl 3:38
Gray JA (1982) The neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system. Oxford University Press, Oxford
Hargreaves R, Lin J (1992) Blood-brain transfer of the CCK antagonists L-365,260 and devazepide. In: Multiple cholecystokinin receptors in the CNS. Dourish CT, Cooper SJ, Iversen SD, Iversen LL, (eds) Oxford University Press, Oxford
Harro J, Vasar E (1991) Cholecystokinin-induced anxiety: How is it reflected in studies on exploratory behaviour. Neurosci Biochem Rev 15:473–477
Hendrie CA, Neill JC, Shepherd JK, Dourish CT The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 1993 Oct; 54(4):689–693
Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell D, Hunter JC, Pinnock RD, Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728–6732
Jackson A, Tattersall D, Bentley G, Rycroft W, Bourson A, Hargreaves R, Tricklebank M, Iversen SD (1994) An investigation into the discriminative stimulus and reinforcing properties of the CCKB-receptor antagonist, L-365,260, in rats. Neuropeptides 26:343–353
Kamin L, Brimer C, Black AH (1963) Conditioned suppression as a monitor of fear of the CS in the course of avoidance learning. J Comp Physiol Psychol 56:497–501
Kramer MS, Cutler N, Ballenger J, Patterson W, Mendels J, Chenault A, Shrivasta R, Matzura-Wolfe D, Lines C, Reines S (1995) A placebo controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Kramer et al. Biol Psychiat 37:462–466
Nevins ME, Anthony EW (1994) Antagonists at the serotonin-3 receptor can reduced the fear-potentiated startle response in the rat: evidence for different types of anxiety. J Pharmacol Exp Ther 268:248–254
Palmour RM, Ervin FR, Bradwejn J, Howbert J (1991) Anxiogenic and cardiovascular effects of CCK-4 in monkeys are blocked by the CCK-B anatgonist LY262691. Soc Neurosci Abstr 17:637.1
Patel S, Chapman KL, Heald A, Smith AJ, Freedman SB (1994) Measurement of central nervous system activity of systemically administered CCKB receptor antagonists by ex vivo binding. Eur J Pharmacol 253:237–244
Powell KR, Barrett JE (1991) Evaluation of the effects of PD 1343-8 (CI-988), a CCKB antagonist, on the punished responding of squirrel monkeys. Neuropeptides 10:75–78
Rataud J, Darche F, Piot O, Stutzmann JM, Bohme GA, Blanchard JC (1991) “Anxiolytic” effect of CCK-antagonists on plus-maze behavior in mice. Brain Res 548:315–317
Rupniak NMJ, Schaffer L, Siegl P, Iversen SD (1993) Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus monkeys. Neuropeptides 25:115–119
Showell GA, Bourrain S, Neduveil JG, Fletcher SR, Baker R, Watt AP, Fletcher AE, Freedman SB, Kemp JA, Marshall GR, Patel S, Smith AJ, Matassa VG (1994) L-740,093: high affinity and potent, water soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonist containing a cationic solubilising group. J Med Chem 37:719–721
Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass AV, Woodruff GN (1991) The behavioural properties of CI-988, a selective cholecystokininBreceptor antagonist. Br J Pharmacol 104:239–245
Traub M, Lines C, Ambrose J (1993) CCK and anxiety in normal volunteers. Br J Clin Pharmacol 36:504P
Tricklebank MD, Honore T, Iversen SD, Kemp Knight JA, Marshall GA, Rupniak NMJ, Singh L, Tye S, Watjen F, Wong EHF (1990) The pharmacological properties of the imidazobenzodiazepine, FG 8205, a novel partial agonist at the benzodiazepine receptor. Br J Pharmacol 101:753–761
Weissman BA, Barrett JE, Brady LS, Witkin JM, Mendelson WB, Paul SM, Skolnick P (1984) Behavioural and neurochemical studies on the anticonflict actions of buspirone. Drug Dev Res 4:93
Author information
Authors and Affiliations
Additional information
All the experiments reported in this manuscript were conducted within British Government Home Office approved techniques, procedures and project licences
Rights and permissions
About this article
Cite this article
Dawson, G.R., Rupniak, N.M.J., Iversen, S.D. et al. Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology 121, 109–117 (1995). https://doi.org/10.1007/BF02245597
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245597